<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1728-8800-2022-3394</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-3394</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ИШЕМИЧЕСКАЯ БОЛЕЗНЬ СЕРДЦА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CORONARY HEART DISEASE</subject></subj-group></article-categories><title-group><article-title>Особенности реваскуляризации миокарда и анализ конечных точек через год наблюдения у больных с острыми и хроническими формами ишемической болезни сердца в зависимости от наличия или отсутствия сахарного диабета</article-title><trans-title-group xml:lang="en"><trans-title>Analysis of myocardial revascularization and endpoints after a 1-year follow-up of patients with acute and chronic coronary artery disease, depending on diabetes presence</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мамедов</surname><given-names>М. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Mamedov</surname><given-names>M. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мехман Ниязи оглы Мамедов— доктор медицинских наук, профессор, руководитель отдела вторичной профилактики хронических неинфекционных заболеваний.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">mmamedov@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8820-9436</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Марданов</surname><given-names>Б. У.</given-names></name><name name-style="western" xml:lang="en"><surname>Mardanov</surname><given-names>B. U.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Баходир Умаркулович Марданов — кандидат медицинских наук, старший научный сотрудник отдела вторичной профилактики хронических неинфекционных заболеваний.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">mmamedov@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2211-8160</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кокожева</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kokozheva</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мадина Алиевна Кокожева — аспирант отдела вторичной профилактики хронических неинфекционных заболеваний.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">mmamedov@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7307-1502</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шукуров</surname><given-names>Ф. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Shukurov</surname><given-names>F. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Фирдавс Баходурович Шукуров — старший научный сотрудник отдела инновационных эндоваскулярных методов профилактики и лечения сердечно-сосудистых заболеваний, врач рентгенэндоваскулярных методов диагностики и лечения.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">mmamedov@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6707-5128</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ахундова</surname><given-names>Х. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Akhundova</surname><given-names>H. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Хумра Рамизовна Ахундова — соискатель отдела вторичной профилактики хронических неинфекционных заболеваний.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">mmamedov@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9844-3122</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Куценко</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kutsenko</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Владимир Александрович Куценко — младший научный сотрудник лаборатории биостатистики отдела эпидемиологии хронических неинфекционных заболеваний.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">mmamedov@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ Национальный медицинский исследовательский центр терапии и профилактической медицины Минздрава России</institution></aff><aff xml:lang="en"><institution>National Medical Research Center for Therapy and Preventive Medicine</institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУ Национальный медицинский исследовательский центр терапии и профилактической медицины Минздрава Росси</institution></aff><aff xml:lang="en"><institution>National Medical Research Center for Therapy and Preventive Medicine</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>03</day><month>11</month><year>2022</year></pub-date><volume>21</volume><issue>10</issue><fpage>3394</fpage><lpage>3394</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Мамедов М.Н., Марданов Б.У., Кокожева М.А., Шукуров Ф.Б., Ахундова Х.Р., Куценко В.А., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Мамедов М.Н., Марданов Б.У., Кокожева М.А., Шукуров Ф.Б., Ахундова Х.Р., Куценко В.А.</copyright-holder><copyright-holder xml:lang="en">Mamedov M.N., Mardanov B.U., Kokozheva M.A., Shukurov F.B., Akhundova H.R., Kutsenko V.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/3394">https://cardiovascular.elpub.ru/jour/article/view/3394</self-uri><abstract><sec><title>Цель</title><p>Цель. Анализ особенностей реваскуляризации миокарда у больных острой и хронической формами ишемической болезни сердца (ИБС) и с различным гликемическим статусом, а также оценка осложнений через год наблюдения.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В проспективное сравнительное клиническое исследование включены 202 больных обоего пола с острыми и хроническими формами ИБС. В зависимости от гликемического статуса и формы ИБС больные были распределены в четыре группы: острые формы ИБС и сахарного диабета 2 типа (СД2); острые формы ИБС без СД2 (контрольная группа); хронические формы ИБС и СД2; хронические формы ИБС без СД2 (контрольная группа). В зависимости от клинического состояния и результатов коронарной ангиографии пациентам проводили различные виды реваскуляризации миокарда: баллонная ангиопластика без стентирования, стентирование, коронарное шунтирование, стентирование + коронарное шунтирование. Через год после выписки со всеми пациентами связывались для оценки осложнений и конечных точек, к числу которых относили повторный инфаркт миокарда, острое нарушение мозгового кровообращения, повторную госпитализацию, повторную реваскуляризацию и смерть. Проведена оценка суммарного показателя конечных точек.</p></sec><sec><title>Результаты</title><p>Результаты. До 80% больным острыми и хроническими формами ИБС вне зависимости от гликемического статуса была проведена реваскуляризация, в основном — стентирование. Частота стентирования среди лиц без СД2 с острой и хронической формами ИБС была достоверно выше по сравнению с больными СД2. Абсолютное число пациентов с коронарным шунтированием, в т.ч. в сочетании со стентированием было больше в группах с СД2. В группах без СД2 количество пациентов с одним стентом оказалось в 2-2,5 раза выше по сравнению с группами, имеющими СД2 — острые формы ИБС (p=0,041) и хронические формы ИБС (p=0,017). По частоте имплантации ≥2 стентов группы не различались. В течение 1 года после выписки среди лиц с острой и хронической формами ИБС и СД2 наблюдается больше госпитализаций и повторных вмешательств. По количеству нефатальных и фатальных осложнений группы между собой не различались, хотя абсолютные цифры этих показателей оказались выше у больных с СД2. Суммарные показатели конечных точек у лиц с СД2 вне зависимости от формы ИБС были в 2 раза выше по сравнению с соответствующими контрольными группами (p&lt;0,001).</p></sec><sec><title>Заключение</title><p>Заключение. Большинство пациентов с острой и хронической формами ИБС вне зависимости от гликемического статуса подверглись реваскуляризации миокарда. У пациентов без СД2 преобладало стентирование, чаще всего одной коронарной артерии. Больным СД2 наряду со стентированием проводилось коронарное шунтирование, а также сочетание этих двух процедур. Через год наблюдения число осложнений у больных СД2 оказалось в 2 раза больше по сравнению с пациентами без СД2, что подчеркивает важность проведения вторичной профилактики, включая комплексную медикаментозную коррекцию.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To analyze myocardial revascularization in patients with acute and chronic coronary artery disease (CAD) and with different glycemic status, as well as to evaluate complications after a 1-year follow-up.</p></sec><sec><title>Material and methods</title><p>Material and methods. This prospective comparative clinical study included 202 patients of both sexes with acute and chronic coronary artery disease. Depending on the glycemic status and CAD type, the patients were divided into four groups: acute CAD and type 2 diabetes (T2D); acute CAD without T2D (control group); chronic CAD and T2D; chronic CAD without DM2 (control group). Depending on the clinical condition and the results of coronary angiography, patients underwent various types of myocardial revascularization: balloon angioplasty without stenting, stenting, coronary artery bypass grafting, stenting + coronary artery bypass grafting. One year after discharge, all patients were contacted to evaluate complications and endpoints, which included recurrent myocardial infarction, cerebrovascular accident, readmission, revascularization, and death. Total indicator of endpoints was assessed.</p></sec><sec><title>Results</title><p>Results. Up to 80% of patients with acute and chronic CAD, regardless of glycemic status, underwent revascularization, mainly stenting. The prevalence of stenting among persons without T2D with acute and chronic CAD was significantly higher compared with patients with T2D. The absolute number of patients with coronary artery bypass grafting, including in combination with stenting, was higher in the T2D groups. In groups without T2D, the number of patients with one stent was 2-2,5 times higher compared to groups with T2D — acute CAD (p=0,041) and chronic CAD (p=0,017). The prevalence of implantation of ≥2 stents did not differ between the groups. Within 1 year after discharge, there were more hospitalizations and reoperations among people with acute and chronic CAD and T2D. The groups did not differ in the number of non-fatal and fatal complications, although the absolute numbers of these indicators were higher in patients with T2D. The total number of endpoints in T2D people, regardless of the CAD type, were 2 times higher compared to the corresponding control groups (p&lt;0,001).</p></sec><sec><title>Conclusion</title><p>Conclusion. Most patients with acute and chronic CAD, regardless of glycemic status, underwent myocardial revascularization. In patients without T2D, stenting prevailed, most often of one coronary artery. Patients with T2D, along with stenting, underwent coronary bypass grafting, as well as a combination of these two procedures. After a year of follow-up, the number of complications in patients with T2D was 2 times higher compared to patients without type 2 diabetes, which emphasizes the importance of secondary prevention, including complex drug treatment.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>реваскуляризация миокарда</kwd><kwd>ишемическая болезнь сердца</kwd><kwd>сахарный диабет</kwd><kwd>конечные точки</kwd></kwd-group><kwd-group xml:lang="en"><kwd>myocardial revascularization</kwd><kwd>coronary artery disease</kwd><kwd>diabetes</kwd><kwd>endpoints</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Драпкина О.М., Концевая А.В., Калинина А.М. и др. Профилактика хронических неинфекционных заболеваний в Российской Федерации. Национальное руководство 2022. Кардиоваскулярная терапия и профилактика. 2022;21(4):3235. doi:10.15829/1728-8800-2022-3235.</mixed-citation><mixed-citation xml:lang="en">Drapkina OM, Kontsevaya AV, Kalinina AM, et al. 2022 Prevention of chronic non-communicable diseases in the Russian Federation. National guidelines. Cardiovascular Therapy and Prevention. 2022;21(4):3235. (In Russ.) doi:10.15829/1728-8800-2022-3235.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Шальнова С.А., Драпкина О.М. Значение исследования ЭССЕ-РФ для развития профилактики в России. Кардиоваскулярная терапия и профилактика. 2020;19(3):2602. doi:10.15829/1728-8800-2020-2602.</mixed-citation><mixed-citation xml:lang="en">Shalnova SA, Drapkina OM. Significance of the ESSE-RF study for the development of prevention in Russia. Cardiovascular Therapy and Prevention. 2020;19(3):2602. (In Russ.) doi:10.15829/1728-8800-2020-2602.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Драпкина О. М., Мамедов М. Н., Руденко Б.А. Атлас ангиографических картин у больных сахарным диабетом. М. 2022. 210 с. ISBN 978-5-6047282-0-8.</mixed-citation><mixed-citation xml:lang="en">Drapkina OM, Mamedov MN, Rudenko BA. Atlas of Angiography in Patients with Diabetes. M., 2022. 210 p. (In Russ.) ISBN 978-5-6047282-0-8.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Алгоритмы специализированной медицинской помощи больным сахарным диабетом; Под ред. И. И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 9-й вып. (дополн.). М., 2019. 212 с. ISBN 978- 5-6043776-5-9. doi:10.14341/DM221S1.</mixed-citation><mixed-citation xml:lang="en">Algorithms of specialized medical care for patients with diabetes mellitus; Ed. by I.I. Dedova, M. V. Shestakova, A.Yu. Mayorova. 9-th ed. (updated). M., 2019. 212 p. (In Russ.) doi:10.14341/DM221S1.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Nanayakkara N, Curtis AJ, Heritier S, et al. Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analyses. Diabetologia. 2021;64(2):275-87. doi:10.1007/s00125-020-05319-w.</mixed-citation><mixed-citation xml:lang="en">Nanayakkara N, Curtis AJ, Heritier S, et al. Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analyses. Diabetologia. 2021;64(2):275-87. doi:10.1007/s00125-020-05319-w.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Ledru F, Ducimetiere P, Battaglia S, et al. New diagnostic criteria for diabetes and coronary artery disease: Insights from an angiographic study. J Am Coll Cardiol. 2001;37:1543-50.</mixed-citation><mixed-citation xml:lang="en">Ledru F, Ducimetiere P, Battaglia S, et al. New diagnostic criteria for diabetes and coronary artery disease: Insights from an angiographic study. J Am Coll Cardiol. 2001;37:1543-50.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Кокожева М. А., Марданов Б. У., Поддубская Е.А. и др. Оценка структурно-функциональных показателей миокарда у пациентов с хронической ишемической болезнью сердца и различным гликемическим статусом. Кардиоваскулярная терапия и профилактика. 2021;20(7):3077. doi:10.15829/1728-8800-2021-3077.</mixed-citation><mixed-citation xml:lang="en">Kokozheva MA, Mardanov BU, Poddubskaya EA, et al. Evaluation of structural and functional parameters of the myocardium in patients with chronic coronary heart disease and various glycemic status. Cardiovascular Therapy and Prevention. 2021;20(7):3077. (In Russ.) doi:10.15829/1728-8800-2021-3077.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Moreno PR, Murcia AM, Palacios IF, et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation. 2000;102:2180-4.</mixed-citation><mixed-citation xml:lang="en">Moreno PR, Murcia AM, Palacios IF, et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation. 2000;102:2180-4.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Marso SP, Mercado N, Maehara A, et al. Plaque composition and clinical outcomes in acute coronary syndrome patients with metabolic syndrome or diabetes. JACC Cardiovasc Imaging. 2012;5:S42-52. doi:10.1016/j.jcmg.2012.01.008.</mixed-citation><mixed-citation xml:lang="en">Marso SP, Mercado N, Maehara A, et al. Plaque composition and clinical outcomes in acute coronary syndrome patients with metabolic syndrome or diabetes. JACC Cardiovasc Imaging. 2012;5:S42-52. doi:10.1016/j.jcmg.2012.01.008.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Рекомендации ESC/EACTS по реваскуляризации миокарда 2018. Российский кардиологический журнал. 2019;24(8):151-226. doi:10.15829/1560-4071-2019-8-151-226.</mixed-citation><mixed-citation xml:lang="en">2018 ESC/EACTS guidelines on myocardial revascularization. Russian Journal of Cardiology. 2019;(8):151-226. (In Russ.) doi:10.15829/1560-4071-2019-8-151-226.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Бузуртанова М.Б., Дидигова Р. Т., Угурчиева З. О. др. Клинико-анатомические особенности миокарда по данным инвазивных и неинвазивных методов исследования у больных ишемической болезнью сердца в сочетании с сахарным диабетом. Кардиоваскулярная терапия и профилактика. 2019;18(3):18-23. doi:10.15829/1728-8800-2019-3-18-23.</mixed-citation><mixed-citation xml:lang="en">Buzurtanova MB, Didigova RT, Ugurchieva ZO, et al. Clinical and anatomical features of the myocardium according to invasive and non-invasive research methods in patients with coronary heart disease in combination with diabetes mellitus. Cardiovascular Therapy and Prevention. 2019;18(3):18-23. (In Russ.) doi:10.15829/1728-8800-2019-3-18-23.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Fearon WF, Nishi T, De Bruyne B, et al.; FAME 2 Trial Investigators. Clinical outcomes and costeffectiveness of fractional flow reserve-guided percutaneous coronary intervention in patients with stable coronary artery disease: Three-year follow-up of the FAME 2 trial (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation). Circulation. 2018;137:480-7. doi:10.1161/CIRCULATIONAHA.117.031907.</mixed-citation><mixed-citation xml:lang="en">Fearon WF, Nishi T, De Bruyne B, et al.; FAME 2 Trial Investigators. Clinical outcomes and costeffectiveness of fractional flow reserve-guided percutaneous coronary intervention in patients with stable coronary artery disease: Three-year follow-up of the FAME 2 trial (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation). Circulation. 2018;137:480-7. doi:10.1161/CIRCULATIONAHA.117.031907.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">BARI Study Group 2D, Frye RL, August P, Brooks MM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360:2503-15. doi:10.1056/NEJMoa0805796.</mixed-citation><mixed-citation xml:lang="en">BARI Study Group 2D, Frye RL, August P, Brooks MM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360:2503-15. doi:10.1056/NEJMoa0805796.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Shehab A, Bhagavathula AS, Al-Rasadi K, et al. Diabetes and Mortality in Acute Coronary Syndrome: Findings from the Gulf COAST Registry. Curr Vasc Pharmacol. 2020;18(1):68-76. doi:10.2174/1570161116666181024094337.</mixed-citation><mixed-citation xml:lang="en">Shehab A, Bhagavathula AS, Al-Rasadi K, et al. Diabetes and Mortality in Acute Coronary Syndrome: Findings from the Gulf COAST Registry. Curr Vasc Pharmacol. 2020;18(1):68-76. doi:10.2174/1570161116666181024094337.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Мамедов М. Н., Канорский С. Г. Международные исследования в кардиологии. М.: Фонд Кардиопрогресс. 2021. 176 c. ISBN 978-5-9905730-6-2.</mixed-citation><mixed-citation xml:lang="en">Mamedov MN, Kanorskiy SG. International clinical trials in cardiology. М.: Cardioprogress. 2021. 176 p. (In Russ.) ISBN 978-5-9905730-6-2.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Zubaid M, Rashed W, Alsheikh-Ali AA, et al. Disparity in STsegment Elevation Myocardial Infarction Practices and Outcomes in Arabian Gulf Countries (Gulf COAST Registry). Heart Views. 2017;18(2):41-6. doi:10.4103/HEARTVIEWS.HEARTVIEWS_113_16.</mixed-citation><mixed-citation xml:lang="en">Zubaid M, Rashed W, Alsheikh-Ali AA, et al. Disparity in STsegment Elevation Myocardial Infarction Practices and Outcomes in Arabian Gulf Countries (Gulf COAST Registry). Heart Views. 2017;18(2):41-6. doi:10.4103/HEARTVIEWS.HEARTVIEWS_113_16.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Imamura F, Mukamal KJ, Meigs JB, et al. Risk factors for type 2 diabetes mellitus preceded by β-cell dysfunction, insulin resistance, or both in older adults: the Cardiovascular Health Study. Am J Epidemiol. 2013;177(12):1418-29. doi:10.1093/aje/kws440.</mixed-citation><mixed-citation xml:lang="en">Imamura F, Mukamal KJ, Meigs JB, et al. Risk factors for type 2 diabetes mellitus preceded by β-cell dysfunction, insulin resistance, or both in older adults: the Cardiovascular Health Study. Am J Epidemiol. 2013;177(12):1418-29. doi:10.1093/aje/kws440.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Luscher TF, Creager MA, Beckman JA, Cosentino F. Diabetes and vascular disease: Pathophysiology, clinical consequences, and medical therapy: Part II. Circulation. 2003;108:1655-61. doi:10.1161/01.CIR.0000089189.70578.E2.</mixed-citation><mixed-citation xml:lang="en">Luscher TF, Creager MA, Beckman JA, Cosentino F. Diabetes and vascular disease: Pathophysiology, clinical consequences, and medical therapy: Part II. Circulation. 2003;108:1655-61. doi:10.1161/01.CIR.0000089189.70578.E2.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Chang M, Lee CW, Ahn JM, et al. Comparison of outcome of coronary artery bypass grafting versus drug-eluting stent implantation for non-ST-elevation acute coronary syndrome. Am J Cardiol. 2017;120:380-6. doi:10.1016/j.amjcard.2017.04.038.</mixed-citation><mixed-citation xml:lang="en">Chang M, Lee CW, Ahn JM, et al. Comparison of outcome of coronary artery bypass grafting versus drug-eluting stent implantation for non-ST-elevation acute coronary syndrome. Am J Cardiol. 2017;120:380-6. doi:10.1016/j.amjcard.2017.04.038.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Mohr FW, Morice MC, Kappetein AP, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet. 2013;381:629-38. doi:10.1016/S0140-6736(13)60141-5.</mixed-citation><mixed-citation xml:lang="en">Mohr FW, Morice MC, Kappetein AP, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet. 2013;381:629-38. doi:10.1016/S0140-6736(13)60141-5.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Head SJ, Milojevic M, Daemen J, et al. Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. Lancet. 2018;391(10124):939-48. doi:10.1016/S0140-6736(18)30423-9.</mixed-citation><mixed-citation xml:lang="en">Head SJ, Milojevic M, Daemen J, et al. Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. Lancet. 2018;391(10124):939-48. doi:10.1016/S0140-6736(18)30423-9.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Lehto HR, Winell K, Pietilä A, et al. Outcomes after coronary artery bypass grafting and percutaneous coronary intervention in diabetic and non-diabetic patients. Eur Heart J Qual Care Clin Outcomes. 2021:qcab065. doi:10.1093/ehjqcco/qcab065.</mixed-citation><mixed-citation xml:lang="en">Lehto HR, Winell K, Pietilä A, et al. Outcomes after coronary artery bypass grafting and percutaneous coronary intervention in diabetic and non-diabetic patients. Eur Heart J Qual Care Clin Outcomes. 2021:qcab065. doi:10.1093/ehjqcco/qcab065.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Figtree GA, Vernon ST, Hadziosmanovic N, et al. Mortality in STEMI patients without standard modifiable risk factors: a sexdisaggregated analysis of SWEDEHEART registry data. Lancet. 2021;397(10279):1085-94. doi:10.1016/S0140-6736(21)00272-500.</mixed-citation><mixed-citation xml:lang="en">Figtree GA, Vernon ST, Hadziosmanovic N, et al. Mortality in STEMI patients without standard modifiable risk factors: a sexdisaggregated analysis of SWEDEHEART registry data. Lancet. 2021;397(10279):1085-94. doi:10.1016/S0140-6736(21)00272-500.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
